

# Seeking novel academic research and assets in immuno-oncology to treat solid tumour cancers

Launch date: Tuesday 31st January 2023

Deadline for submissions: Tuesday 14th March 2023

The submission form starts on page 3

We invite academic researchers and technology transfer offices to share with us non-confidential details of any opportunities targeting solid tumour cancers by harnessing the immune system. We are looking to uncover new research, technologies and assets that will lead to the development of new cancer immunotherapies, or improve the efficacy or availability of existing immunotherapies, through collaboration with industry.

There are no associated costs or requirements for an IN-PART subscription to engage with this campaign.

Through the campaign, we are leveraging our matchmaking platforms (Connect and Discover), in-house STEM expertise, and our highly engaged networks across academia and industry to work towards developing new solutions addressing this global challenge.

The R&D leads at each of our company partners have shared an overview of their priorities and requirements from academia below, and will be evaluating all the relevant opportunities submitted in response to them. These priorities will also be discussed in more detail through live Q&A in our virtual event series.

View the R&D priorities of companies involved in the campaign seeking new submissions from academia:

- MSD
- Tocris Bioscience (a Bio-Techne company)
- Immunitas Therapeutics







## Run in partnership with:



**Labiotech.eu** is the leading digital media covering the global biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. <u>Learn</u> more.



**ASTP**: Europe's premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. **Learn more.** 



**PraxisAuril**: A world-leading professional association for knowledge exchange practitioners, whose network includes 5000+ KE professionals. **Learn more**.



**BIA:** The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. **Learn more**.



#### Also part of our R&D network, the following companies have shared their interests:

Servier

Of particular interest is next-generation immuno-oncology research that will improve and surpass existing therapies for solid tumour cancers. Within scope are:

- Immune checkpoint inhibitors
- Cell therapy
- Monoclonal antibodies
- Cancer vaccines
- Tumour microenvironment targeting
- Immune system modulation
- Novel immuno-oncology targets/target imaging

### What's out of scope?

- Research not centring around immunotherapy
- Therapeutics targeting liquid tumours should be applicable to solid tumour cancers

### Who should respond to the campaign?

Our global R&D network is actively engaged and interested in collaborating with and commercialising research submitted by

- Technology transfer offices
- Industry engagement and research services teams
- Academic researchers

#### How to submit your opportunity:

If you are an academic researcher, **or** you work in a technology transfer office **not** subscribed to IN-PART's matchmaking platform, Connect:

Use the submission form below to outline non-confidential details of a project, research or technology and submit it along with any associated high-res graphics or figures by email to <a href="mailto:submissions@in-part.co.uk">submissions@in-part.co.uk</a>.

If you work at an institute that **is** subscribed to IN-PART's matchmaking platform, Connect: You can upload submissions as normal **directly through your dashboard.** 

Universities with relevant technologies already on IN-PART can email their dedicated Account Manager to request their inclusion in our open research directory, white paper, and associated communications around the campaign.

### **Further details:**

For more information on IN-PART Global Challenges and past campaigns, please visit our Global Challenge homepage.

Don't hesitate to contact our team who will be able to help with any questions regarding the global challenge or your submission via: <a href="mailto:submissions@in-part.co.uk">submissions@in-part.co.uk</a>. To learn more about IN-PART please see our website: <a href="mailto:in-part.co">in-part.co</a>.

# **Submission form:**



# Project/Research/Technology Title:

This should be no longer than 20 words.

Contact Information: Name:
Title:
Email:
Institute and Department:
If you are a researcher, please provide the name and email address of your associated case manager or point of contact in your TTO or business engagement team (if applicable):

# **Background Information:**

Please keep this brief (under 300 words). Please provide a brief summary (a couple of paragraphs is fine) of how the research, technology or project fits into the wider context of how immunotherapies can effectively treat solid tumour cancers

# Research/Technology Overview:



An overview of the technology/solution/innovation/expertise.

(200-300 words). Please provide an overview of the technology/solution/innovation/expertise. This should include (where available) non-confidential technical information, the overall goal, clinical rationale and novelty of the approach, data tables, figures or videos (where applicable). If images or videos are provided, please attached these as high-resolution files alongside the submission form.

# What is the development stage of the research or technology?

Please use definitions related to the technology sector, e.g. for therapeutics: Discovery, target identification, target validation, hit generation, compound screening, lead generation, in vitro, in vivo, or preclinical validation.

# **Benefits:** Outline the specific advantages over existing solutions (eg, faster, more accurate). A list of bullet points will suffice but more details can be provided if available. **Applications:** Potential use cases and/or markets A list of bullet points will suffice but more details can be provided if available. **Opportunity:** What types of opportunities are you looking for in terms of working with industry to help further develop

and/or commercialise the project/technology?

# Seeking:



# What types of industry collaboration are you looking for?

Development partner Commercial partner Licensing University spin-out Seeking investment

# **IP and Legal Considerations:**

Is all of the information you have provided non-confidential?

Please note that all information submitted must be non-confidential

# What is the IP status of the research/technology?

Patented (if so, please provide details on the patent ID)
Patent application submitted (if so, please provide details on the application ID)
Provisional patent (if so, please provide details on the patent ID)
No patent
Know-how based
Copyright

#### Patent details:

If you are a researcher, have you disclosed this technology to your technology transfer office?

Are you submitting this project to be sent to any of the companies working on this campaign?

MSD
Tocris, a Bio-Techne brand
Immunitas Therapeutics

<u>Servier</u>

If you would **not** like your submission to be promoted on our public channels, such as social media, white paper or top innovation lists please let us know here: